Applying the Evidence on Antifibrotic Agents for IPF

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

Comorbidities and Selection of DMTs

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

Conventional and Stereotactic Radiotherapy for Lung Cancer

Upon completion of the activity, participants should be able to: •Distinguish the main types of radiation therapy (conventional and stereotactic) used for lung cancer •Discuss outcomes for Stage III lung cancer with various conventional treatment approaches •Explain recent experience with stereotactic ablative radiotherapy (SAbR), especially for treatment of patients with Stage I tumo...
The France Foundation

Early MS: Induction Therapy and Escalation Strategies

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

Elizabeth: Loves the outdoors but bothered by persistent cough and GERD

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

Environmental Influences on the Development of Pulmonary Fibrosis

Conference Coverage: Live from Nashville!
The France Foundation

Exploring New Therapeutic Avenues for Managing PF

Conference Coverage: Live from Nashville!
The France Foundation

Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis

Conference Coverage: Live from Nashville!
The France Foundation

Exploring the Patient Journey: Let’s Talk About ILD and IPF

Early referral and treatment is important! Join Dr. Amy Olson in this series of exciting, fast-paced videos on ILD and IPF.
The France Foundation

Exploring the Patient Journey: Let’s Talk About ILD and IPF

This discussion highlights the challenges with IPF diagnosis, explains when to refer, analyzes the need for personalized medicine, and demonstrates how to keep patients on treatment.
The France Foundation

Fleischner Society Update in Classification of IPF

Conference coverage from the CHEST Annual Meeting
The France Foundation

Gene Abnormalities and ILD

Conference Coverage: Live from Nashville!
The France Foundation

Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis

Conference Coverage: Live from Nashville!
The France Foundation

Getting to Goal Can Be Difficult: Brian

Explore options for treating T2DM with new interactive, multimedia cases that provide specifics on the practical aspects of patient management of T2DM. Each case is an individualized experience in which patient outcomes depend on learner choices. Improve your skills while earning AMA PRA Category 1 Credit™.
The France Foundation

Getting to Goal Can Be Difficult: Louise

Explore options for treating T2DM with new interactive, multimedia cases that provide specifics on the practical aspects of patient management of T2DM. Each case is an individualized experience in which patient outcomes depend on learner choices. Improve your skills while earning AMA PRA Category 1 Credit™.
The France Foundation

Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

ICD-10 Codes and Nomenclature for Classification of PAH

CHEST Annual Meeting Conference Coverage
The France Foundation

Image-Guided Thermal Ablation of Lung Cancer

Upon completion of the activity, participants should be able to: •Explore recognized standards of care for thermal ablation of NSCLC as reflected in relevant treatment guidance, with special attention to imaging-related concerns and combination of IO and conventional treatment •Review clinical trial data describing efficacy and safety of ablative therapies
The France Foundation

IPF Management Considerations

CHEST Annual Meeting Conference Coverage
The France Foundation

Is the delivery system a good match for your patients with COPD?

Drs. Gary T. Ferguson and Nicola A. Hanania address the following questions: •How often should the importance of optimizing inhaled delivery devices and patient preference/needs be reviewed? •What are the clues that an inhaled delivery system might not be working well for a specific patient? •What is known about gaps between patients and pulmonologists with regard to inhaler devices sys...
The France Foundation

Lung Cancer Pathology: From Atypical Adenomatous Hyperplasia to Adenocarcinoma

Upon completion of the activity, participants should be able to: •Explore lung adenocarcinoma classification, with a focus on the transition from pre-invasive to invasive adenocarcinoma •Examine how imaging and molecular testing inform histologic findings in lung adenocarcinoma classification and comprehension of the transition from pre-invasive to invasive disease •Describe data suppor...
The France Foundation

Lung Cancer Screening

LEARNING OBJECTIVES Upon completion of the activity, participants should be able to: •Review historical RCTs of lung cancer screening •Explore the purpose and utility of the ACR Lung-RADS™ •Identify individuals who may benefit from lung cancer screening
The France Foundation

Lung Cancer: Standard of Care Treatment Algorithms (Chemotherapy/Immunotherapy)

Upon completion of the activity, participants should be able to: •Review the current treatment algorithms for lung cancer •Identify appropriate roles for systemic therapy in various stages of lung cancer •Explain tumor-specific factors that influence selection of systemic treatment modalities
The France Foundation

Management of Breakthrough Disease Activity in MS

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

New Approaches to the Diagnosis of IPF

Conference Coverage: Live from Nashville!
The France Foundation

New Developments in the Diagnosis and Management of IPF

CHEST Annual Meeting Conference Coverage
The France Foundation

New Research on Mechanisms in the Development of PF

Conference Coverage: Live from Nashville!
The France Foundation

NTM and Treatment Strategies for Patients with Cavitary Disease

CHEST Annual Meeting Conference Coverage
The France Foundation

Palliative Care for Patients with IPF

CHEST Conference Coverage Annual Meeting
The France Foundation

Perspectives on Side Effect Management Strategies with Pirfenidone and Nintedanib

CHEST Annual Meeting Conference Coverage
The France Foundation

Real World Experience in Patients with COPD

CHEST Conference Coverage Annual Meeting
The France Foundation

Registry Data Provide Important Severity Indicators for PH

CHEST Annual Meeting Conference Coverage
The France Foundation

Staging and Diagnosis of Lung Cancer

Upon completion of the activity, participants should be able to: •Discuss the role of imaging in lung cancer diagnosis and staging •Review descriptors identified in the 8th Edition of TNM Staging for Lung Cancer •Review methods for tissue acquisition for lung cancer diagnosis and mediastinal staging
The France Foundation

Stepping up or stepping down – which direction for COPD patients?

Drs. Gary T. Ferguson and James F. Donohue address the following questions: •What are new findings related to LAMA/LABA fixed dose combinations? •What are the considerations and issues with stepping up to triple therapy? •When is it safe and appropriate to step down from triple therapy to a LAMA/LABA fixed dose combination?
The France Foundation

Targeting B-cells in Primary Progressive MS (PPMS)

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

The Gut Microbiota in MS

Upon completion of this activity, participants should be better able to: •Integrate new and emerging information on the pathophysiology of MS, including modifiable risk factors, in the development of individualized treatment plans •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

The Latest in IPF: Implications for Clinical Practice

CHEST Annual Meeting Conference Coverage
The France Foundation

The Role of Surgery for Non-Small Cell Lung Cancer

Upon completion of the activity, participants should be able to: •Explore different surgical approaches to NSCLC •Determine the extent of resection required based on the patient’s surgical risk and tumor factors •Review data from clinical trials examining the role of different surgical strategies of patients with NSCLC
The France Foundation

Toni: Too tired to continue teaching and experiencing painful heartburn

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

Transbronchial Cryobiopsy for the Diagnosis of ILD

Conference coverage from the CHEST Annual Meeting
The France Foundation

Updates on Registry Enrollment and Growth of the Care Center Network

Conference Coverage: Live from Nashville!
The France Foundation

Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS

Upon completion of this activity, participants should be better able to: •Integrate new and emerging information on the pathophysiology of MS, including modifiable risk factors, in the development of individualized treatment plans •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

What Do the Experts Say about New Developments in the Diagnosis of ILD?

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

What’s Next for IPF Therapy?

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

What’s the 2017 GOLD standard for managing patients with COPD?

Drs. James Donohue and Gary Ferguson discuss changes regarding the management of COPD and new recommendations regarding the use of ICS.
The France Foundation

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.